With the emergence of advanced diagnostic techniques such as PSMA PET-CT and the findings from recent studies, it is reasonable to anticipate a shift and update in the treatment of patients with cN1M0 PCa. This evidence concerns the gene FOLH1 and posterior cortical atrophy.